Genelux is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat tumor types. The company operates in the biotechnology and pharmaceutical industries, which are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary rights. The company's product candidates are based on a novel approach to the treatment of cancer, a field with only one FDA-approved viral immunotherapy to date, talimogene laherparepvec (IMLYGIC).

Genelux faces significant competition from many sources, including pharmaceutical, biopharmaceutical and biotechnology companies, academic institutions, and government agencies. Many potential competitors have substantially greater financial, technical and other resources. For platinum-resistant/refractory ovarian cancer (PRROC), competitors include Abbvie's ELAHERE, Roche/Genentech's AVASTIN, Merck & Co.'s KEYTRUDA, GSK's ZEJULA, and AstraZeneca's LYNPARZA, among others. For non-small cell lung cancer (NSCLC), competitors include Roche/Genentech, Merck & Co., Astrazeneca, Novartis, Pfizer, Johnson & Johnson, Eli Lilly & Co., and Bristol Myers Squibb. For small cell lung cancer (SCLC), competitors include Amgen, Roche/Genentech, Merck & Co., Astrazeneca and Bristol Myers Squibb. The company believes its product candidates, if and when marketed, would largely complement rather than compete directly with existing treatment options.

Genelux generates revenue through license agreements, having recognized revenue of $0.01 million ¹ relating to its license agreement with ELIAS Animal Health, LLC for each of the years ended December 31, 2025 and 2024. The company has never generated any revenue from commercially approved product sales. Its primary business model is the research and development of oncolytic viral immunotherapies, with a focus on advancing its lead product candidate, Olvi-Vec, through clinical trials and seeking regulatory approval. The company's product candidates are intended to be 'off-the-shelf' personalized immunotherapies that selectively kill tumor cells and induce a robust immune response against a patient's tumor neoantigens.

The company's lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary, modified strain of the vaccinia virus (VACV). Olvi-Vec is being evaluated in three clinical trials: a Phase 3 registrational trial (OnPrime/GOG-3076) in the U.S. for platinum-resistant/refractory ovarian cancer (PRROC), a Phase 2 clinical trial (VIRO-25) in the U.S. for recurrent non-small cell lung cancer (NSCLC), and a Phase 1b/2 clinical trial in China for recurrent small cell lung cancer (SCLC). The Phase 3 PRROC trial is an open-label, randomized control design (2:1 randomization) enrolling patients who are platinum resistant/refractory by standard definitions and received a minimum of 3 prior lines of therapy. The Phase 2 VIRO-25 trial is an open-label, randomized and controlled clinical trial. The Phase 1b/2 SCLC trial is evaluating safety and tolerability.

Beyond Olvi-Vec, Genelux has developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates using its proprietary CHOICE platform. The company has over 500 different versions of the VACV armed with greater than 110 transgenes ², having a variety of engineered attributes. These provide potential utility in multiple tumor types in both monotherapy and combination therapy settings. The company's patent portfolio as of December 31, 2025 consisted of 12 issued U.S. patents ³, 9 issued foreign patents ⁴, and 7 pending foreign patent applications ⁵, which relate generally to the composition of current and potential future products, their methods of use and methods of manufacture. Issued patents are expected to expire between 2026 and 2038 ⁶.

In March 2025, Genelux completed an underwritten offering of 3,000,000 ⁷ shares of its common stock at an offering price of $3.50 ⁸ per share, with total net proceeds of $9.6 million ⁹. In January 2026, the company completed an underwritten follow-on public offering of 6,666,667 ¹⁰ shares of its common stock at an offering price of $3.00 ¹¹ per share, with total net proceeds of $18.5 million ¹². In May 2024, the company completed an underwritten offering of 7,500,000 ¹³ shares of common stock and accompanying warrants to purchase 7,500,000 ¹⁴ shares at a combined offering price of $4.00 ¹⁵ per share, with total net proceeds of $27.7 million ¹⁶. The company also entered into a license agreement with Newsoara BioPharma Co. Ltd. in September 2021, receiving an aggregate of $11.0 million ¹⁷ ($5.0 million ¹⁸ as an upfront payment and $6.0 million ¹⁹ as a milestone payment). Newsoara is obligated to pay additional development and commercial milestone payments up to $160.5 million ²⁰ in the aggregate.

For the fiscal year ended December 31, 2025, Genelux reported a net loss of $32.1 million ²¹ compared to a net loss of $29.9 million ²² for the fiscal year ended December 31, 2024. Total operating expenses were $33.2 million ²³ in 2025 versus $31.7 million ²⁴ in 2024. Research and development expenses were $19.9 million ²⁵ in 2025, up from $19.0 million ²⁶ in 2024. General and administrative expenses were $13.4 million ²⁷ in 2025, compared to $12.7 million ²⁸ in 2024. As of December 31, 2025, the company had an accumulated deficit of $283.5 million ²⁹ and cash, cash equivalents, restricted cash and marketable securities of $14.6 million ³⁰.

A primary growth vector is the advancement of Olvi-Vec through late-stage clinical development focused on platinum resensitization. The Phase 3 OnPrime/GOG-3076 registration trial in PRROC is ongoing, with topline results anticipated in the second half of 2026 ³¹. The company is also evaluating Olvi-Vec in a Phase 2 VIRO-25 trial for recurrent NSCLC and a Phase 1b/2 trial for recurrent SCLC in China, with additional interim readouts expected throughout 2026 ³². The company intends to prepare for a U.S. commercial launch in ovarian cancer as the clinical trial program progresses.

Another key growth vector is leveraging the CHOICE discovery platform to build a portfolio of oncology product candidates. The company has generated over 500 different versions of the VACV armed with greater than 110 transgenes ³³. Genelux also plans to seek additional development and commercial collaborations for Olvi-Vec and other product candidates while retaining economic and commercial rights in key geographic areas like the United States. The collaboration with Newsoara is expected to support clinical and commercial development of Olvi-Vec in China, with a co-sponsored Phase 1b/2 clinical trial in recurrent SCLC ongoing and potential initiation of a trial in recurrent ovarian cancer in China.

Management expects research and development costs to increase significantly for the foreseeable future as the company commences and conducts clinical trials and continues development of current and future product candidates. General and administrative expenses are also anticipated to increase to support expected growth in research and development activities and as the company expands its business operations. The company expects to continue to incur significant and increasing operating losses for the foreseeable future.

Genelux is broadening and strengthening its internal manufacturing capabilities. The company has a cGMP manufacturing facility in San Diego, California, which is producing material for ongoing clinical trials and is intended for the initial commercial launch of Olvi-Vec, if approved. The company also leases a second building in the same location which, when upgrades are completed, will provide laboratory capabilities and administrative offices. The company has developed a new process for larger-scale manufacturing using a closed, mammalian-cell-based production system, which is being implemented in its manufacturing facility.

The company's capital allocation strategy includes funding research and development activities, which are central to its business model. For the year ended December 31, 2025, research and development expenses were $19.9 million ³⁴. The company has raised capital through public offerings, including $9.6 million ³⁵ in net proceeds from a March 2025 offering and $18.5 million ³⁶ in net proceeds from a January 2026 offering. The company does not anticipate declaring or paying any cash dividends for the foreseeable future. As of December 31, 2025, the company had sold an aggregate of 5,460 ³⁷ shares of common stock under an at-the-market offering program, which was terminated in March 2026.

A significant headwind is the company's need for substantial additional financing to advance the development of Olvi-Vec and any future product candidates. The company expects that its existing cash, cash equivalents, restricted cash and marketable securities, totaling $14.6 million ³⁸ at December 31, 2025, and subsequent net proceeds of $18.5 million ³⁹ received in January 2026, representing a pro forma balance of $33.1 million ⁴⁰, will fund planned operations into the first quarter of 2027 ⁴¹. The company's independent registered public accounting firm included a 'going concern' explanatory paragraph in its report, indicating substantial doubt about the company's ability to continue as a going concern.

Geopolitical and macroeconomic factors are identified as constraints, including the impact of tariffs and trade barriers, which could increase research and development expenses and disrupt the supply chain. The company also faces risks related to the current administration's policies, including potential reductions in drug prices through initiatives like Most-Favored-Nation pricing and the Medicare Drug Price Negotiation Program. Additionally, disruptions to the operations of the FDA and other regulatory agencies due to funding shortages or staffing cuts could delay the review and approval of the company's product candidates.

Management's message emphasizes the company's focus on executing its late-stage clinical program for Olvi-Vec to demonstrate platinum-resensitization in multiple indications. Key strategic priorities include advancing the Phase 3 OnPrime/GOG-3076 registrational trial in PRROC, with topline results anticipated in the second half of 2026 ⁴⁸, and reporting additional interim data from the Phase 2 VIRO-25 NSCLC trial and the Phase 1b/2 SCLC trial throughout 2026 ⁴⁹. Management also highlights the importance of preparing for a U.S. commercial launch in ovarian cancer, broadening internal manufacturing capabilities, and leveraging the CHOICE discovery platform to build a portfolio of oncology product candidates. The company expects its existing cash, cash equivalents, restricted cash and marketable securities, totaling $14.6 million ⁵⁰ at December 31, 2025, and subsequent net proceeds of $18.5 million ⁵¹ received in January 2026, representing a pro forma balance of $33.1 million ⁵², to fund planned operations into the first quarter of 2027 ⁵³.

For the fiscal year ended December 31, 2025, total revenues were $0.008 million ⁵⁴, unchanged from $0.008 million ⁵⁵ in fiscal 2024. Net loss was $32.145 million ⁵⁶ compared to a net loss of $29.869 million ⁵⁷ in the prior year. Diluted net loss per share was $0.86 ⁵⁸ versus $0.95 ⁵⁹ in the prior year. Operating loss was $33.214 million ⁶⁰ in 2025, compared to $31.696 million ⁶¹ in 2024. Total other income was $1.069 million ⁶² in 2025, down from $1.827 million ⁶³ in 2024, primarily due to lower bond accretion income of $0.358 million ⁶⁴ and a gain on extinguishment of accounts payable of $0.370 million ⁶⁵ in 2024. As of December 31, 2025, the company had cash, cash equivalents and restricted cash of $5.333 million ⁶⁶ and marketable securities of $9.262 million ⁶⁷, compared to $8.565 million ⁶⁸ and $22.330 million ⁶⁹, respectively, at December 31, 2024. Stockholders' equity was $11.544 million ⁷⁰ at December 31, 2025, down from $26.274 million ⁷¹ at December 31, 2024. Research and development expenses increased by $0.853 million ⁷² to $19.851 million ⁷³ in 2025, driven by a $0.845 million ⁷⁴ increase in clinical and regulatory expenses. General and administrative expenses increased by $0.665 million ⁷⁵ to $13.371 million ⁷⁶ in 2025, primarily due to a $1.121 million ⁷⁷ increase in employee compensation.

The company has incurred significant losses since inception, with net losses of $32.1 million ⁴² and $29.9 million ⁴³ for the years ended December 31, 2025 and 2024, respectively, and an accumulated deficit of $283.5 million ⁴⁴ as of December 31, 2025. The company will require substantial additional financing to advance the development of Olvi-Vec, and its independent registered public accounting firm has included a 'going concern' explanatory paragraph, indicating substantial doubt about its ability to continue as a going concern. The company currently has only one product candidate, Olvi-Vec, in clinical development, and a failure of this candidate would adversely affect the business and may require discontinuation of other product candidates based on the same therapeutic approach. The company's product candidates are based on a novel approach to cancer treatment, making it difficult to predict the time and cost of development, and the FDA has limited experience with the approval of viral immunotherapies. The company faces significant competition from companies with substantially greater financial resources, and its ability to obtain, maintain and protect its intellectual property rights is uncertain, with a patent portfolio of 12 issued U.S. patents ⁴⁵, 9 issued foreign patents ⁴⁶, and 7 pending foreign patent applications ⁴⁷ as of December 31, 2025.